DGAP-News: WILEX AG starts first patient study with MEK inhibitor WX-554
(firmenpresse) - DGAP-News: WILEX AG / Key word(s): Study
WILEX AG starts first patient study with MEK inhibitor WX-554
11.04.2012 / 07:13
---------------------------------------------------------------------
PRESS RELEASE
WILEX starts first patient study with MEK inhibitor WX-554
Munich, 11 April 2012. WILEX AG (ISIN DE0006614720 / WL6 / Frankfurt Stock
Exchange) announces today the start of a Phase Ib/II trial with the
small-molecule MEK inhibitor WX-554. The open-label, dose-escalation study
will investigate the safety, pharmacokinetics, pharmacodynamics and
clinical activity of WX-554 in patients with solid tumours.
After a dose escalation part to confirm the biologically effective dose, a
dose expansion part will follow, enriched for patients with MEK pathway
relevant mutations, to investigate initial clinical activity.
The UK Medicines and Healthcare products Regulatory Agency (MHRA) approved
this Phase Ib/II trial with WX-554 in January 2012. The study is being
conducted within the Experimental Cancer Medicine Centre (ECMC) network in
the UK which is jointly supported by Cancer Research UK and the Departments
of Health for England, Scotland, Wales and Northern Ireland. The goal of
the ECMC Network initiative and the 19 involved cancer centres across the
UK is to drive the development of new therapies to bring benefits to
patients faster.
About WX-554
The small-molecule MEK inhibitor is one of five oncology preclinical
programmes obtained under the strategic alliance agreed with UCB Pharma
S.A. in January 2009 and is being clinically developed by WILEX. Mitogen
activated protein kinase (MEK) has been shown to play a central role in
signal transduction. The MEK signalling pathway is over expressed in more
than 30% of cancers, resulting in uncontrolled cell growth and
proliferation. The first two Phase I trials were successfully completed in
2010 and 2012. These healthy volunteer studies showed that both,
intravenously and orally administered WX-554 were safe and well tolerated.
About WILEX AG
WILEX AG is a biopharmaceutical company based in Munich, Germany. Focused
on oncology, the company has a broad portfolio of diagnostic and
therapeutic products for the specific detection and targeted treatment of
various types of cancer. The company's therapeutic product candidates are
based on antibodies (RENCAREX(R) in Ph III) and small molecules
(MESUPRON(R) in Ph II, WX-554 in Ph Ib/II and WX-037 early stage). In the
diagnostic segment WILEX has REDECTANE(R), an antibody based in vivo
diagnostic imaging agent in a Phase III-programme. The US subsidiary WILEX
Inc. in Cambridge, MA, WILEX markets a portfolio of research use only and
in vitro diagnostic tests under the brand Oncogene Science. These
diagnostic tests could be developed as companion diagnostics in clinical
trials and for therapy monitoring. The subsidiary Heidelberg Pharma GmbH
offers an attractive and highly promising antibody drug conjugate
technology platform and a pre-clinical service business. The business model
of WILEX comprises research, technology, product development as well as
sales and marketing. WILEX's customers and partners include leading
international pharmaceutical companies.
Website: http://www.wilex.com, ISIN DE0006614720 / WKN 661472 / Symbol WL6
Contact
Katja Arnold (CIRO)
Corporate Communications
WILEX AG
Grillparzerstr. 10
81675 Munich, Germany
Tel.: +49 (0)89-41 31 38-126
Fax: +49 (0)89-41 31 38-99
E-Mail: mailto:investors(at)wilex.com
This communication contains certain forward-looking statements relating to
the Company's business, which can be identified by the use of
forward-looking terminology such as 'estimates', 'believes', 'expects',
'may', 'will' 'should' 'future', 'potential' or similar expressions or by a
general discussion of the Company's strategy, plans or intentions. Such
forward-looking statements involve known and unknown risks, uncertainties
and other factors, which may cause our actual results of operations,
financial position, earnings, achievements, or industry results, to be
materially different from any future results, earnings or achievements
expressed or implied by such forward-looking statements. Given these
uncertainties, prospective investors and partners are cautioned not to
place undue reliance on such forward-looking statements. We disclaim any
obligation to update any such forward-looking statements to reflect future
events or developments.
End of Corporate News
---------------------------------------------------------------------
11.04.2012 Dissemination of a Corporate News, transmitted by DGAP - a
company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: WILEX AG
Grillparzerstr. 10
81675 München
Germany
Phone: +49 (0)89 41 31 38 - 0
Fax: +49 (0)89 41 31 38 - 99
E-mail: info(at)wilex.com
Internet: www.wilex.com
ISIN: DE0006614720
WKN: 661472
Listed: Regulierter Markt in Frankfurt (Prime Standard);
Freiverkehr in Berlin, Düsseldorf, München, Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------
164363 11.04.2012
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: EquityStory
" alt="Dorex Minerals Inc. Completes Phase 1 of Exploration on Tres Hermanos Gold Mine
Datum: 11.04.2012 - 07:13 Uhr
Sprache: Deutsch
News-ID 133666
Anzahl Zeichen: 6008
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 181 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: WILEX AG starts first patient study with MEK inhibitor WX-554"
steht unter der journalistisch-redaktionellen Verantwortung von
WILEX AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
